Cross talk about the role of Neuropeptide Y in CNS disorders and diseases.
Animal models
CNS disease
Clinical studies
Neuropeptide Y
Preclinical studies
Y-receptors
Journal
Neuropeptides
ISSN: 1532-2785
Titre abrégé: Neuropeptides
Pays: Netherlands
ID NLM: 8103156
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
08
08
2023
revised:
18
10
2023
accepted:
20
10
2023
medline:
20
11
2023
pubmed:
3
11
2023
entrez:
2
11
2023
Statut:
ppublish
Résumé
A peptide composed of a 36 amino acid called Neuropeptide Y (NPY) is employed in a variety of physiological processes to manage and treat conditions affecting the endocrine, circulatory, respiratory, digestive, and neurological systems. NPY naturally binds to G-protein coupled receptors, activating the Y-receptors (Y1-Y5 and y6). The findings on numerous therapeutic applications of NPY for CNS disease are presented in this review by the authors. New targets for treating diseases will be revealed by medication combinations that target NPY and its receptors. This review is mainly focused on disorders such as anxiety, Alzheimer's disease, Parkinson's disease, Huntington's disease, Machado Joseph disease, multiple sclerosis, schizophrenia, depression, migraine, alcohol use disorder, and substance use disorder. The findings from the preclinical studies and clinical studies covered in this article may help create efficient therapeutic plans to treat neurological conditions on the one hand and psychiatric disorders on the other. They may also open the door to the creation of novel NPY receptor ligands as medications to treat these conditions.
Identifiants
pubmed: 37918268
pii: S0143-4179(23)00069-0
doi: 10.1016/j.npep.2023.102388
pii:
doi:
Substances chimiques
Neuropeptide Y
0
Receptors, Neuropeptide Y
0
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102388Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflict of interest, financial or otherwise.